Recent Progress in Polymer Therapeutics as Nanomedicines - Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity, and Applications - page 111

5. Alexis, F., et al., Factors affecting the clearance and biodistribution of
polymeric nanoparticles. Mol Pharm, 2008. 5 (4): p. 505-515.
6. Davis, M.E., The first targeted delivery of siRNA in humans via a self-
assembling, cyclodextrin polymer-based nanoparticle: from concept to
clinic. Mol Pharm, 2009. 6 (3): p. 659-668.
7. Perrault, S.D., et al., Mediating tumor targeting efficiency of nanoparticles
through design. Nano Lett, 2009. 9 (5): p. 1909-1915.
8. Alberts B., B.D., Johnson A., Lewis J., Raff M., Roberts K., Walter P.,
Essential Cell Biology . 1998, New York: Garland Publishing. 472-477.
9. Pan H. and K. J., Multifunctional Water-Soluble Polymers for Drug
Delivery , in Multifunctional Pharmaceutical Nanocarriers , M. Ferrari,
Editor. 2008, Springer. p. 81-142.
10. Satchi-Fainaro, R., R. Duncan, and C.M. Barnes, Polymer therapeutics for
cancer: Current status and future challenges , in Polymer Therapeutics
II: Polymers as Drugs, Conjugates and Gene Delivery Systems . 2006,
Springer-Verlag Berlin: Berlin. p. 1-65.
11. Markman, M., Improving the toxicity profile of chemotherapy for
advanced ovarian cancer: a potential role for CT-2103. J Exp Ther Oncol,
2004. 4 (2): p. 131-136.
12. Langer, C.J., CT-2103: a novel macromolecular taxane with potential
advantages compared with conventional taxanes. Clin Lung Cancer,
2004. 6 Suppl 2 : p. S85-S88.
13. Pawar, R., et al., A. Polysaccharides as carriers of bioactive agents
for medical application. Natural-Based Polymers for Biomedical
Applications, ed. R.L.E. Reis. 2008, New York: Woodhead Pub. 50.
14. Caliceti, P., S. Salmaso, and S. Bersani, Polysaccharide-base anticancer
prodrugs . Macromolecular Anticancer Therapeutics, ed. P.E.
Harivardhan R.L.; Couvreur. 2010, New York: Humana Press. 163-
220.
15. Pasut, G. and F.M. Veronese, PEG conjugates in clinical development
or use as anticancer agents: an overview. Adv Drug Deliv Rev, 2009.
61 (13): p. 1177-1188.
16. Duncan, R., Development of HPMA copolymer-anticancer conjugates:
clinical experience and lessons learnt. Adv Drug Deliv Rev, 2009. 61 (13):
p. 1131-1148.
17. Kopecek, J. and P. Kopeckova, HPMA copolymers: origins, early
developments, present, and future. Adv Drug Deliv Rev, 2010. 62 (2): p.
122-149.
18. Chun, L., Poly(L-glutamic acid)-anticancer drug conjugates. Adv Drug
Deliv Rev, 2002. 54 : p. 695-713.